Cashman Neil
Chief Scientific Officer
Cashman Neil has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 3, 2026.
On the most recent filing, Cashman Neil is listed as Chief Scientific Officer at ProMIS Neurosciences Inc. Inside the rolling window, Cashman Neil reported 1 open-market purchase totaling $39K in PMN and no open-market sales.
Companies traded
Other insiders at PMN
Insider Buying
$39K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Cashman Neil made?
Cashman Neil has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Cashman Neil trade?
Cashman Neil has filed SEC Form 4 disclosures for 1 company, including PMN.
When was Cashman Neil's most recent SEC Form 4 filing?
Cashman Neil's most recent SEC Form 4 filing on Tracefour is dated Nov 3, 2026.
What is Cashman Neil's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Cashman Neil is listed as Chief Scientific Officer.
What is Cashman Neil's total buy and sell value in the current window?
Inside the rolling retention window, Cashman Neil bought $39K and sold $0 based on SEC Form 4 filings.
What was Cashman Neil's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 10,000 PMN shares on 2026-11-02, worth $39K, per SEC Form 4 filings.